Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07357415 · ClinicalTrials.gov registry record · Phase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT07357415 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 600 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT07357415, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Conditions Studied
Interventions
- DRUG Retatrutide
Study Locations (20)
Texas
- Velocity Clinical Research, Dallas - Dallas
- Cedar Health Research - Texas Native Health - Dallas
- Cedar Health Research - Dallas
- Cedar Health Research - Fort Worth - Fort Worth
California
- Care Access - Huntington Beach - Huntington Beach
- Los Angeles Institute for Metabolic Research - Los Angeles
Florida
- New Horizon Research Center - Miami
- Encore Medical Research - Weston - Weston
New York
- NYC Research INC - Long Island City
- Weill Cornell Medical College - New York
Arizona
- Arizona Research Center - Phoenix
Hawaii
- Pacific Diabetes & Endocrine Center - Honolulu
Kentucky
- L-MARC Research Center - Louisville
Massachusetts
- Brigham and Women's Hospital Diabetes Program - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2026-01-24 |
| Est. Completion | 2028-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07357415
The ClinicalTrials.gov registry entry for NCT07357415 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Retatrutide is the first listed.
NCT07357415 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07357415 about?
NCT07357415 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight". The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
What is the current status of trial NCT07357415?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2026-01-24. Estimated completion is 2028-11.
What conditions does trial NCT07357415 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07357415?
The interventions under investigation include: Retatrutide (DRUG).
Who is sponsoring clinical trial NCT07357415?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07357415 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Hawaii, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.